Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 8;37(6):767-785.
doi: 10.1016/j.ccell.2020.04.005. Epub 2020 May 14.

Dietary Approaches to Cancer Therapy

Mylène Tajan  1 , Karen H Vousden  2
Affiliations
Free article
Review

Dietary Approaches to Cancer Therapy

Mylène Tajan et al. Cancer Cell. .
Free article

Abstract

The concept that dietary changes could improve the response to cancer therapy is extremely attractive to many patients, who are highly motivated to take control of at least some aspect of their treatment. Growing insight into cancer metabolism is highlighting the importance of nutrient supply to tumor development and therapeutic response. Cancers show diverse metabolic requirements, influenced by factors such as tissue of origin, microenvironment, and genetics. Dietary modulation will therefore need to be matched to the specific characteristics of both cancers and treatment, a precision approach requiring a detailed understanding of the mechanisms that determine the metabolic vulnerabilities of each cancer.

Keywords: Diet; cancer; metabolism; nonessential amino acids; therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests K.H.V. is on the Board of Directors and shareholder of Bristol Myers Squibb, a shareholder of GRAIL Inc, and on the Science Advisory Board (with stock options) of PMV Pharma, RAZE Therapeutics, and Volastra Therapeutics. She is also on the Scientific Advisory Board of Ludwig Cancer. K.H.V. is a co-founder and consultant of Faeth Therapeutics, funded by Khosla Ventures. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of patent application WO/2017/144877.

Publication types

LinkOut - more resources